Q0239 HCPCS Level II code: Injection, bamlanivimab-xxxx, 700 mg
CMS terminated Q0239: its last date of service was Apr 16, 2021. It stays here for looking up older claims; newer services need a current code.
Official description
Q0239Injection, bamlanivimab-xxxx, 700 mg
Short description: Bamlanivimab-xxxx
HCPCS · United States
Medicare details
The indicators CMS publishes with Q0239 in its October 2026 file. They describe Medicare’s handling, not another payer’s.
- Medicare coverage
- Carrier judgment
- Medicare pricing
- Vaccinations
- Type of service
- Pneumococcal/flu vaccine
- BETOS category
- Immunizations/Vaccinations
- Added
- Nov 9, 2020
- Terminated after
- Apr 16, 2021
Where Q0239 sits
- 1Q codesTemporary codes
- 2Terminated Q0239Injection, bamlanivimab-xxxx, 700 mg
Source and release
- Data release
- HCPCS Level II · October 2026
- Effective date
- Oct 1, 2026
- Publisher
- CMS
This page is built from the HCPCS Level II catalog that Vero Codes reads when it suggests codes: Centers for Medicare & Medicaid Services’s October 2026 release, imported from the publisher’s file and checked against it. The description, notes and structured data come from the same record.
Frequently asked questions
Is HCPCS code Q0239 still valid?
No. CMS terminated Q0239; its last date of service was Apr 16, 2021. It is listed for looking up services from before then. Use a current code for newer services.
Does Medicare cover Q0239?
CMS lists Q0239’s Medicare coverage as “Carrier judgment” and its pricing as “Vaccinations”. Coverage and payment still depend on the patient, the setting, the documentation and the payer.
Which HCPCS Level II release does this page use?
It uses CMS’s October 2026 release, in effect from Oct 1, 2026 to Dec 31, 2026. It is a reference: confirm the code against the current list and the payer’s rules before you submit it.
Codes beside Q0239
All Q codesQ0222Injection, bebtelovimab, 175 mgQ0224Injection, pemivibart, for the pre-exposure prophylaxis only, for certain adults and adolescents (12 years of age and older weighing at least 40 kg) with no known sars-cov-2…Q0234Injection, tocilizumab-bavi, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive…Q0235Injection, monoclonal antibody products with an indication for post-exposure prophylaxis or treatment of covid-19, for hospitalized adults and/or pediatric patients who are…Q0237Injection, tocilizumab-anoh, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive…Q0238Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive…Q0240Injection, casirivimab and imdevimab, 600 mgQ0243Injection, casirivimab and imdevimab, 2400 mgQ0244Injection, casirivimab and imdevimab, 1200 mgQ0245Injection, bamlanivimab and etesevimab, 2100 mgQ0247Injection, sotrovimab, 500 mgQ0249Injection, tocilizumab, for hospitalized adults and pediatric patients (2 years of age and older) with covid-19 who are receiving systemic corticosteroids and require…